Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
نویسندگان
چکیده
Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 Matthew Taylor, Scott Antonia, Johanna Bendell, Emiliano Calvo, Dirk Jäger, Filippo de Braud, Patrick A Ott, M Catherine Pietanza, Leora Horn, Dung T Le, Michael A Morse, José A López-Martin, Paolo A Ascierto, Olaf Christensen, Jason S Simon, Chen-Sheng Lin, Joseph Paul Eder
منابع مشابه
An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
Background Patients with advanced NSCLC are treated with first-line PT-DC, which is associated with a median OS of 8–10 months and 1-year and 2-year survival rates of 30–40% and 10–15%, respectively. Nivolumab (a fully human IgG4 anti-programmed death-1 immune checkpoint inhibitor antibody) alone and in combination with ipilimumab (a fully human IgG4 cytotoxic T-lymphocyte antigen-4 immune chec...
متن کاملBreast irradiation therapy innovations forgo permanent marks, minimize treatment.
Many women who had radiotherapy for breast cancer bear small, dark ink dots on their chest—a permanent reminder of diagnosis and treatment. Radiation oncologists use these to mark the area to irradiate. But many patients are reluctant to receive these permanent body markings, which can be visible in bathing suits and other clothing. Steven Landeg, M.Sc., senior radiographer, and colleagues at t...
متن کاملRationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
BACKGROUND Treatments of non-small-cell lung cancer (NSCLC)-particularly of the squamous subtype-are limited. In this article, we describe the immunomodulatory environment in NSCLC and the potential for therapeutic targeting of the immune system through cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) immune-checkpoint pathway blockade. MATERIALS AND METHODS We searched...
متن کاملSurvival and Prognostic Factors in Small Cell Lung Cancer Patients in Turkey
Background: Small cell lung cancer (SCLC) is a highly aggressive tumor. Objective: To evaluate the survival and time to progression of patients with SCLC admitted to a chest disease center in Istanbul, Turkey. Methods: Based on the reports of a pulmonary oncology clinic, data regarding performance status (PS), clinical stage of disease, treatment, time to progression and survival of 67 patients...
متن کاملPhase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade 3-4 drug-related toxicity to ipilimumab. We report long-term survival, response duration, and biomarkers in the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 3 شماره
صفحات -
تاریخ انتشار 2015